A Phase IIIb Multicenter, Open-label, Single Arm Study to Evaluate the Efficacy and Safety of Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Pasireotide (Primary)
- Indications Acromegaly
- Focus Registrational; Therapeutic Use
- Acronyms SWITCH
- Sponsors Novartis
- 03 Oct 2017 Planned End Date changed from 6 Aug 2018 to 29 Aug 2018.
- 03 Oct 2017 Planned primary completion date changed from 6 Aug 2018 to 29 Aug 2018.
- 10 Jun 2017 Biomarkers information updated